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Background: Ischemic heart disease (IHD) is the most common cause of heart failure (HF); however, the role of
revascularization in these patients is still unclear. Consensus on proper use of cardiac imaging to help determine
which candidates should be considered for revascularization has been hindered by the absence of clinical studies
that objectively and prospectively compare the prognostic information of each test obtained using both standard
and advanced imaging.
Methods/Design: This paper describes the design and methods to be used in the Alternative Imaging Modalities in
Ischemic Heart Failure (AIMI-HF) multi-center trial. The primary objective is to compare the effect of HF imaging strategies
on the composite clinical endpoint of cardiac death, myocardial infarction (MI), cardiac arrest and re-hospitalization for
cardiac causes.
In AIMI-HF, patients with HF of ischemic etiology (n = 1,261) will follow HF imaging strategy algorithms according to the
question(s) asked by the physicians (for example, Is there ischemia and/or viability?), in agreement with local practices.
Patients will be randomized to either standard (SPECT, Single photon emission computed tomography) imaging
modalities for ischemia and/or viability or advanced imaging modalities: cardiac magnetic resonance imaging (CMR) or
positron emission tomography (PET). In addition, eligible and consenting patients who could not be randomized, but
were allocated to standard or advanced imaging based on clinical decisions, will be included in a registry.
Discussion: AIMI-HF will be the largest randomized trial evaluating the role of standard and advanced imaging
modalities in the management of ischemic cardiomyopathy and heart failure. This trial will complement the results of the
Surgical Treatment for Ischemic Heart Failure (STICH) viability substudy and the PET and Recovery Following
Revascularization (PARR-2) trial. The results will provide policy makers with data to support (or not) further investment in
and wider dissemination of alternative ‘advanced’ imaging technologies.
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The multifaceted Canada-Finland collaborative research
program, Imaging Modalities to Assist with Guiding
Therapy and the Evaluation of Patients with Heart Failure
(IMAGE-HF), is designed with the following overall ob-
jectives: 1) to determine the impact of emerging imaging
strategies on relevant clinical outcomes and decision
making in patients with HF; 2) to establish standardized
quality assurance (QA) measures and central databases in
order to achieve reliable outcome driven research; and 3)
to apply this as a platform for evaluation of new and
emerging imaging and serum biomarkers in HF. The pro-
gram consists of three separate randomized controlled tri-
als. Project 1A is designed to compare the effect of HF
imaging strategies in the evaluation and diagnosis of is-
chemic heart disease (IHD). Project 1B evaluates the util-
ity of cardiac magnetic resonance (CMR) imaging in
addition to standard echocardiography in the evaluation
and diagnosis of non-ischemic HF (with either preserved
or reduced ejection fraction) in comparison to the stand-
ard echocardiography alone. Project 1C is comparing two
imaging modalities for the detection of coronary artery
disease (standard coronary angiography versus cardiac
computerized tomography scans).
Project 1A is the focus of this publication
Despite multiple advances in cardiovascular disease, the
morbidity and mortality of patients with heart failure
(HF) in the setting of IHD remains high. Although it is
believed that most patients with symptoms of significant
ischemia may benefit from revascularization, decisions
regarding revascularization in those with advanced ven-
tricular dysfunction and no significant ischemia are
complex, and the applicability of current clinical trial
data is often challenged by limited patient selection.
Over the past three decades, information describing car-
diac structure, function, perfusion, hemodynamics, and
metabolism obtained from noninvasive cardiac imaging
studies has been used to guide management decisions
for patients with HF. Although this anatomic and
physiologic information adds value to clinical care, an
accepted strategy is still debated regarding the optimal
testing sequence approach to efficiently identify the
treatment strategy most likely to improve outcomes.
Consensus on proper use of cardiac imaging studies
has been hindered by absence of clinical studies that ob-
jectively compare the independent treatment-related
prognostic information of each test obtained using
standardized methods. Uniformity of reporting formats
also needs to be improved in order to provide a clearer
working scheme for clinicians.
Alternative Imaging Modalities in Ischemic Heart Fail-
ure (AIMI-HF) (Project I-A of the Imaging Modalities to
Assist with Guiding Therapy and the Evaluation ofPatients with Heart Failure, IMAGE-HF program) is a
multicenter trial with the primary objective of comparing
the effect of HF imaging strategies on the composite clin-
ical endpoint of cardiac death, myocardial infarction (MI),
resuscitated cardiac arrest and cardiac re-hospitalization
(worsening heart failure, acute coronary syndrome,
arrhythmia). Patients with an ischemic heart disease
(IHD) etiology will follow HF imaging strategy algorithms
according to the question(s) asked by the physicians (for
example, is there ischemia and/or viability?), in agreement
with their local clinical practices for standard and alterna-
tive imaging. Patients will be randomized to either stand-
ard imaging modalities for ischemia and/or viability
(SPECT) or advanced imaging modalities, namely cardiac
magnetic resonance imaging (CMR) or positron emission
tomography (PET). Secondary objectives include the effect
of HF imaging strategies on the incidence of revasculariza-
tion procedures, left ventricular remodeling, HF symp-
toms and quality of life, as well as a health economic
evaluation. A biomarker substudy (on renal function, left
ventricular remodeling and a selected set of biomarkers),
assessing mechanisms underlying specific cardiovascular
events, is also planned (see Additional file 1).
Coronary revascularization and ischemic heart failure
Among patients with coronary artery disease (CAD) and
heart failure, mortality rates range from 10 to 60% at 1
year [1-11]. CAD is the most common cause of HF,
however the role of revascularization in these patients is
often unclear. Significant concerns remain about peri-
operative morbidity and mortality [8,10-14]. The recent
Surgical Treatment for Ischemic Heart Failure (STICH)
trial [15] did not demonstrate a significant benefit for
coronary artery bypass graphing (CABG) surgery com-
pared to medical therapy, for the primary endpoint of
all-cause mortality in patients with LV dysfunction (ejec-
tion fraction {“EF”} ≤ 35%) and coronary disease eligible
for CABG; although there was benefit for secondary
endpoints of cardiovascular death and cardiovascular
endpoints. STICH focused on IHD rather than on
chronic HF with systolic dysfunction, and the outcomes
of the many patients who were screened but did not
undergo revascularization remain unknown [16]. Unfor-
tunately, the STICH trial has not provided the final an-
swer on the role of revascularization for patients with
chronic HF; nor did it evaluate the role of advanced im-
aging in decision making for revascularization in this pa-
tient population.
Imaging in ischemic heart failure
Increasingly over the past three decades, information describ-
ing cardiac structure, function, perfusion, hemodynamics, and
metabolism obtained from noninvasive cardiac imaging
studies has been used to guide management decisions for
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information adds value to clinical care, an accepted im-
aging strategy has not evolved that tailors the testing se-
quence to specific presenting features of individual
patients to efficiently identify the treatment strategy most
likely to improve outcomes. Consensus on proper use of
cardiac imaging studies has been hindered by the absence
of clinical studies that objectively compare the independ-
ent treatment-related prognostic information of each test
obtained using standardized methods.
Observational data has demonstrated that methods to de-
fine ischemia, viability and scar can identify high risk patients
likely to benefit (or not) from revascularization [17-22].
The long-term impact of newer or alternative imaging
strategies used for the revascularization decision pro-
cesses has not been evaluated prospectively in HF. Re-
vascularization has the potential to restore function to
dysfunctional viable myocardium but not scar. Our
group and others have shown that patients with dysfunc-
tional but viable hibernating myocardium are at high
risk for cardiac events if they do not undergo timely
revascularization [20,23].
Until recently, data from predominantly observational
studies had shown that when viability is present, patients
have better outcomes with revascularization [24-26].
The PET and Recovery Following Revascularization
(PARR-2) trial [27] represents the largest randomized
study to evaluate viability imaging in patients with severe
LV dysfunction. Overall, there was a trend for benefit for
Fluorodeoxyglucose (18F) positron emission tomgoraphy
scan (FDG PET) assisted management over standard care.
When the adherence to imaging recommendations was
considered, there was a significant outcome benefit. A
high risk subgroup demonstrated a significant mortality
benefit [20,27]. Recently, in a post-hoc analysis a signifi-
cant reduction in events was observed in a subset of pa-
tients at the Ottawa site (Ottawa-FIVE) [28]. The results
suggest outcome benefits can be achieved using FDG PET
in an experienced center with ready access to FDG and in-
teractions with HF and revascularization teams.
Although PARR2 was unique as a randomized con-
trolled trial for imaging viability, it was underpowered
for the primary outcome. Larger prospective randomized
studies are needed, although undertaking such studies
can be challenging [16,29,30]. The STICH viability study
[29] did not include a comparison to late gadolinium en-
hanced CMR, other modalities, nor evaluate the role of
stress induced ischemia. Finally, although care was taken
to standardize imaging acquisition and transfer of data,
standardization was not as rigorous as has recently been
achieved in the CADRE Ontario provincial registry [31].
Results from the STICH Viability substudy [29] sug-
gest that identification of viable myocardium by single
photon emission computed tomography (SPECT) ordobutamine stress echocardiography (DSE) do not add
value in patients selected for surgical revascularization.
The STICH Viability substudy results may be explained
by a patient population that was at lower risk, with pa-
tients already acceptable for revascularization, having
more single vessel disease, infrequent previous CABG,
low incidence of renal dysfunction and predominantly
without heart failure. For such patients, it may be argued
that viability imaging is not needed. This is in contrast
to sicker populations in studies such as PARR2 [20,27],
where physicians were uncertain about revascularization
decisions and, therefore, needed viability assessment. Via-
bility testing was not randomized in STICH [15,16,29].
The authors acknowledged the potential for selection bias
[29]. Furthermore, only 19% of patients in the substudy
were considered to have nonviable myocardium, which is
far less than in most previous studies [29,32,33]. Analyses
combining DSE and SPECT results were performed. Is-
chemia and hibernation imaging were not reported. More
advanced (or alternative) ischemia and viability imaging
modalities (that is, using PET and CMR) were not
evaluated.
Thus the STICH results need to be interpreted cau-
tiously [16,30], and the limitations along with the other
observational and randomized data, justify the need for
a prospective randomized trial to evaluate imaging strat-
egies in patients with heart failure.
AIMI-HF is a large randomized controlled trial, com-
paring ‘advanced imaging technologies’ (PET and CMR)
to standard imaging (SPECT). The findings will provide
policy makers with data to support (or not) further in-
vestment in and dissemination of alternative or advanced
technologies.
Study hypotheses and objectives
Primary hypothesis
In patients with HF due to IHD with left ventricular
ejection fraction (LVEF) ≤ 45%, a management algorithm
that applies alternative imaging strategies (PET or CMR)
achieves a better clinical outcome measured as the com-
posite clinical endpoint of cardiac death, MI, resuscitated
cardiac arrest and cardiac re-hospitalization (hospitalization
due to heart failure, acute coronary syndrome or arrhythmia)
than an approach with standard care using SPECT
imaging.
Secondary hypotheses
1) Compared to standard care, in patients with HF due
to IHD with LVEF ≤45% a management algorithm
that applies alternative imaging modalities (PET or
CMR) achieves: a) more efficient use of
revascularization procedures with similar
complication rates than standard care imaging
strategies; b) better HF and angina symptom
Table 1 Criteria for the clinical diagnosis of heart failure





▪ Pulmonary rales (post cough)
▪ Orthopnea ▪ Jugular venous pressure (JVP) ≥5 cm
above sternal angle
▪ Dyspnea upon mild or
moderate exertion
▪ Lower extremity oedema
▪ Chest x-ray demonstrating pleural
effusion, pulmonary congestion, or
cardiomegaly
aIf LVEF is 30% or less, no signs or symptoms of HF are required for eligibility.
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using MLHFQ and EQ5D; and d) is cost-effective.
2) In patients with HF due to IHD with LVEF ≤45%, a
HF management algorithm that applies PET achieves
a better primary (composite clinical endpoint) and
secondary outcomes (revascularizations, remodeling,
QoL, cost effectiveness) compared to one that
applies CMR.
Primary objective
The primary objective of AIMI-HF is to compare the effect
of HF imaging strategies on the composite clinical end-
point of cardiac death, MI, resuscitated cardiac arrest and
cardiac re-hospitalization (WHF, ACS, and arrhythmia).
Patients with HF due to an ischemic heart disease (IHD)
etiology of LV dysfunction will follow HF imaging strategy
algorithms according to the question(s) asked by the physi-
cians (Is there ischemia and/or viability?), in agreement
with their local practices for standard and alternative
imaging.
Secondary objectives
To compare the effect of HF imaging strategies on:
1. The incidence of revascularization procedures
(percutaneous coronary intervention {PCI}, CABG).
2. LVEF,
3. HF symptoms and New York Heart Association
Functional Class (NYHA) class.
4. QOL (Minnesota Living with Heart Failure
questionnaire (MLHFQ), the EQ5D).
5. Health economics. Costs will be estimated through
regression analysis and cost effectiveness will be
assessed through decision modeling.
6. The safety of imaging tests measured by cumulative
radiation, adverse reactions to imaging contrast
agents and stress testing agents will also be
determined.
Methods/Design
The AIMI-HF is a randomized controlled trial to com-
pare the effectiveness of HF imaging strategies in pa-
tients with HF due to IHD. Patients enrolled will have
LV systolic dysfunction due to IHD where evaluation of
ischemia and viability is relevant. Patients will be allo-
cated in a concealed fashion to standard (SPECT) versus
advanced (PET or CMR) imaging. In addition, a registry
will be maintained of patients undergoing standard or
advanced imaging based on clinical decisions.
A survey sent to participating centers revealed that most
of them could not provide stress echocardiography con-
sistently within the requested timeframe as per the re-
search protocol. This was especially true for dobutamine
stress-echo (DSE) and viability protocols. The decisionnot to include this method was mainly due to statistical
considerations; since if only a few centers elected to use
this standard method, there may not be enough patients
to adequately compare it with other methods (and site
bias might also be involved).
Study participants
Patients with clinical HF (see Table 1 for definition) or
severe LV systolic dysfunction who need further defin-
ition of ischemia, viability or scar and meet the following
inclusion and exclusion criteria, will be considered for
entry into this trial. Patients will be prospectively ran-
domized to standard (SPECT) versus advanced (PET or
CMR) imaging. Patients who meet inclusion criteria but
cannot be randomized due to clinical management deci-
sions, yet undergo standard or advanced imaging, will be
entered into a registry.
Inclusion criteria:
 Age >18 years
and
 Known or highly suspected coronary artery disease
(CAD) documented by coronary angiography or by
history of previous MI or evidence of moderate
ischemia or scar based on prior imaging.
and
 LV dysfunction most likely attributable to ischemic
heart disease with EF ≤45% measured by any
acceptable means (echo, nuclear RNA, PET or
SPECT perfusion, angiography, CMR) within the
previous 6 months and NYHA class II to IV
symptoms within the past 12 months or
 LV dysfunction most likely attributable to ischemic
heart disease with EF ≤30% measured by any
acceptable means (echo, nuclear RNA, PET or
SPECT perfusion, angiography, CMR) within the
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past 12 months.
Exclusion criteria:
 Severe medical conditions that significantly affect
the patient's recommended management (for
example, severe COPD, active metastatic
malignancy) and would preclude revascularization.
 <4 weeks post-ST segment elevation myocardial
infarction (STEMI)
 Already identified as not suitable for
revascularization
 Emergency revascularization indicated
 Severe valvular heart disease requiring valve surgery
 Pregnancy, breast feeding
 Potential for non-compliance to tests involved in
this protocol
 Incapacity to provide informed consent
Randomization
Patients will be randomized according to a pre-defined
randomization scheme and availability of imaging proce-
dures at individual participating centers. All eligible patients
will be randomized to either standard or advanced imaging
modalities for ischemia and/or viability testing. Participating
sites with the capability for two advanced imaging modalities
will then be further randomized between each modality. If
randomization is not possible due to local site factors, the
patient can be entered into the registry (Figure 1). The ratio
of advanced to standard imaging will be 2:1.
Blinding
The study is not blinded given the nature and purpose
of the interventions. Knowledge of imaging results andFigure 1 Overall randomization scheme for patients enrolled in Alternpotential gained from the intervention will need to be
considered to implement the appropriate treatment
strategy. Therefore, performance bias (that is, systematic
differences between groups in the care provided or ex-
posure to factors other than the interventions of inter-
est) and attrition bias (that is, systematic differences
between groups in withdrawals from the study) may
occur. Detection bias is still a potential concern, but an
independent assessor will evaluate the objectively de-
fined primary outcome and an adjudication committee
will independently review and adjudicate each clinical
event blinded to treatment randomization.
Measurements
Standard imaging protocols have been defined by the
IMAGE-HF Standardization team, using nationally rec-
ognized protocols (Additional file 2) GFR will be esti-
mated (eGFR) using the Modified Diet in Renal Disease
(MDRD) equations based on current recommendations
[34-37]. CBC, electrolytes, urea, creatinine will be mea-
sured locally on randomization. This creatinine meas-
urement will serve for local eGFR assessment (to ensure
CMR eligibility). Further laboratory analyses will be
collected and stored for future biomarkers analyses
(at baseline and at 1 year in a subgroup of patients;
Additional file 1).
Subject evaluation
At baseline, demographic and clinical data will be col-
lected from all participants on standardized case report
forms. These data will be collected from the most re-
cent, routine history and physical examination that has
been completed by the treating physician. Quality of life
questionnaires (EuroQol and Minnesota Living with
Heart Failure) will be administered. In addition, theative Imaging Modalities in Ischemic Heart Failure (AIMI-HF).
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To address a secondary objective, whenever possible, an
echocardiogram will be performed if LV ejection fraction
has not been determined by echocardiography within 6
months prior to randomization. As much as possible,
imaging procedures will be performed within 4 weeks
after entry into the trial. Subsequent telephone follow-
up and repeat blood work will be performed on a
predetermined schedule (Table 2). If the patient cannot
be reached by telephone for their final assessment, a
query will be made at government or national health
care resources to verify if any corresponding events have
occurred since the last visit (search of corresponding
codes for cardiac death, MI, cardiac arrest and cardiac
re-hospitalization for WHF, ACS, or arrhythmia). A
follow-up echocardiogram will be requested at one year
(LV remodeling, LVEF). Within 3 months of the baseline
scan the treating physician will be asked to record the
HF management plan.
Safety and ethics
This study was approved by the University of Ottawa
Heart Institute Human Research Ethics Board, protocol
#2010620-01H. In addition, before study initiation at
each site, this protocol, and the informed consent form,
as well as any advertisement for subject recruitment,
was submitted for review and approval by each local par-
ticipating site’s ethics committee charged with this re-
sponsibility and will be so submitted for future sites.
These ethic committees will submit written notification
of the approval to the investigator. This study will be
conducted according to the Declaration of Helsinki,
Good Clinical Practice and the TriCouncil Policy.
Registry
Eligible and consenting patients that could not be ran-
domized but undergo standard or advanced imaging
based on clinical decisions, will be included in a registry.
Measurement, subject evaluation and safety and ethics
as outlined in the previous sections will apply to these
registry patients. The registry patients for advancedTable 2 Patient assessment schedule
Baseline 3 months 6 months 1
Imaging (SPECT, PET or CMR) x
Blood work x
Demographic and history x
Clinical data collected x
EuroQol questionnaire x x x
MLWHF questionnaire x x x
Telephone follow-up x x
CMR cardiac magnetic resonance, MLWHF Minnesota Living with Heart Failure, PET
tomography.imaging will be considered in the sample size calculation
and data analysis (see below); however, the small number
of patients expected to be part of the SPECT registry
will not be considered in the primary analysis.
Sample size
For the sample size determination, the estimated occur-
rence over one year of the composite clinical endpoint
of cardiac death, MI, resuscitated cardiac arrest and car-
diac re-hospitalization (WHF, ACS, arrhythmia) for PET
is 27% and for standard care is 40%, based on the
Ottawa-FIVE substudy [28] of the PARR-2 [27] study in
which the composite event rates were 19% and 41%, re-
spectively. These estimates were considered reasonable
as it reflects the outcome rates that may be achievable at
a facility with expertise and access to FDG PET imaging.
There are no similar data upon which to draw an esti-
mate for CMR. Considering the Schinkel et al. publica-
tion [38], which noted sensitivity of CMR to be between
PET and standard care modalities and based on expert
consensus from our IMAGE-HF workshop (16 Decem-
ber 2008 in Toronto, Canada), we estimate the event
rate for CMR directed care would lie between the above
values at 34%. Hence, an overall rate for the alternative
(PET, CMR) modalities would be approximately 30%.
The rates are considered conservative since the mean
duration of follow-up will be 2 years, whereas the
PARR-2 study was 1 year.
For the primary hypothesis, using the two-sided log-
rank test for comparing advanced (PET + CMR) versus
standard modalities with a 2:1 patient allocation, a sam-
ple size of 495 patients (of which 330 are allocated to
the advance modality and 165 are allocated to the stand-
ard modality) would be needed in order to detect a dif-
ference after 1 year in the composite clinical endpoint of
30% for the advanced modalities (PET, CMR) compared
to 40% for standard care modalities (SPECT). This is cal-
culated with a level of significance of 0.05 and power of
80%, and assuming a uniform accrual of patients over
the 2.5 year recruitment period, a 1 year minimum
follow-up period and a 10% loss from each study group.2 months 18 months 24 months 36 months 48 months
x
x
x x x x x
x x x x x
x x x x x
positron emission tomography, SPECT single photon emission computed
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clinically important difference based on a consensus of
the IMAGE-HF investigators.
For the secondary hypothesis, using the Cox regression
model for comparing the advanced modalities PET ver-
sus CMR with an approximate 1:1 patient allocation, a
sample size of 548 patients per modality is needed con-
sidering an anticipated rate for the composite clinical
endpoint of 30% after 1 year, a level of significance of
0.05, a power of 80% and a loss to follow-up of 10%. The
sample size calculation is complicated by the fact that
766 patients (383 per group) from the registry (in which
patients in the registries were clinically directed to PET
or CMR) will be combined in the analysis with the 330
patients (165 per group) from the randomized part of
the study (in which patients in the randomized study
will be randomly allocated to PET versus CMR versus
standard modality) for a total of 1096 patients (548 per
group). For a sample of 1096 patients, a Cox regression
of the log hazard ratio of the composite clinical endpoint
on the group allocation variable (PET versus CMR) with
a conservative standard deviation of 0.5 (based on an ap-
proximate equal allocation to PET and CMR), achieves
80% power at a 0.05 significance level to detect a 40% in-
crease in the hazard ratio to1.4. This increase in the haz-
ard ratio was deemed to be the minimal clinically
important difference based on a consensus among the
IMAGE-HF investigators. The sample size includes an
adjustment to accommodate confounding by indication
for allocation patients to PET versus CMR by incorpor-
ating a multiple regression of the group allocation vari-
able on the other covariates in the Cox regression
model; a conservative estimate of this confounding was
considered by taking a value of 0.25 for the multiple cor-
relation coefficient R for the relationship between the
group allocation variable and the set of covariates
identified.
The total sample size is thus 1,096 + 165 = 1,261.Statistical analysis
Descriptive statistics will be used to summarize the char-
acteristics of the patients for each imaging technology
on demographic, clinical and site-related factors, and
differences between these groups will be reviewed for
their clinical significance.Analysis populations
For the purposes of data analysis, three study populations
will be considered: Intent-to-treat (ITT) Population, As-
Treated Population and Per-protocol Population. The ITT
population will be used for the main analysis for all pri-
mary and secondary objectives, except for the safety ana-
lysis where the as-treated population will be used. As asecondary analysis, the analyses will be repeated for the
as-treated and per-protocol populations.
Primary analysis (advanced versus standard imaging)
For the primary analysis, the time-to-event of the com-
posite clinical endpoint of cardiac death, MI, arrest and
cardiac re-hospitalization (WHF, ACS, arrhythmia) will
be compared between the advanced modality (PET or
CMR) to an approach with standard care using SPECT
imaging using survival analysis. Kaplan-Meier survival
curves of the primary endpoint will be compared be-
tween the advanced and standard modalities with the
log-rank test. Potential confounding variables of the
relationship between the imaging technologies and the
primary endpoint will be assessed. In particular, pro-
pensity scores based on patient factors (for example,
in/outpatient, NYHA class, HF duration, diabetes,
atrial fibrillation) and site factors (for example, time-to
-imaging, time-to-therapy) will be used in the analysis
if necessary to adjust for potential differences. A Cox
proportional hazard models will be used to assess the
occurrence of the endpoints between the imaging tech-
nologies (model will include a group indicator vari-
able) adjusting for any pertinent baseline differences
identified. The proportional hazards assumption
underlying the Cox model will be assessed.
Secondary outcomes
For the secondary outcomes PCI, CABG, HF symptoms
and NYHA class, chi-square tests will be used to com-
pare the advanced and standard imaging technologies;
logistic regression analysis will be used for adjusting any
pertinent baseline differences identified. For the second-
ary outcomes LVEF, MLHFQ and EQ5D, analysis of vari-
ance will be used to compare trends over time between
the advanced and standard technologies. Analysis of co-
variance will be used for adjusting any pertinent baseline
differences identified.
Economic evaluation
For secondary objective 5, a cost-effectiveness analysis of
advanced versus standard modality groups will be
conducted. Analysis will take the form of a cost-utility
analysis with cost effectiveness assessed in terms of the
incremental cost per quality life year. Analysis will in-
corporate data on resource use and patients utility values
for the period from initiation of treatment to study ter-
mination. Resource use will be assessed through review
of patient charts and patient utility values will be derived
using the EQ5D and MLHF. A decision model will be
created to estimate long-term costs and quality adjusted
life years (QALYs) for all comparators. Uncertainty
within the analysis will be assessed through Monte Carlo
and other simulation techniques.
Table 3 Imaging Modalities to Assist with Guiding
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For the secondary objective 6, safety will be evaluated by
documenting all adverse events. Descriptive statistics
(frequency distributions, numerical descriptors) and 95%
CIs will be calculated. The as-treated population will be
the main analysis population for this safety evaluation.
Secondary analysis (PET versus CMR)
For the secondary analysis, comparing the PET and
CMR modalities, potential confounding variables of the
relationship between the imaging technologies and the
primary endpoint will be assessed. In particular, propen-
sity scores based on patient factors (for example, in/
outpatient, NYHA class, HF duration, diabetes, atrial fib-
rillation) and site factors (for example, time-to-imaging,
time-to-therapy) will be used in the analysis if necessary
to adjust for potential differences between PET and
CMR. A Cox proportional hazard models will be used to
assess the occurrence of the endpoints between the im-
aging technologies (the model will include a group indi-
cator variable) adjusting for any pertinent baseline
differences identified. The proportional hazards assump-
tion underlying the Cox model will be assessed. The sec-
ondary outcomes will be analyzed in a similar fashion.
Missing data
‘Missingness’ is considered to be missing at random
(MAR) and mixed methods repeated measures (MMRM)
and multiple imputation techniques will be used for
handling missing data. In particular, for continuous out-
comes at multiple time points MMRM will be used.
Study management
The IMAGE-HF trial is managed by an Executive Com-
mittee consisting of clinicians specialized in diagnostic
imaging and/or heart failure and experts in biostatistics,
physics and radiochemistry, as well as a larger Steering
Committee consisting of members of the Executive
Committee and representatives of all the initial study
centers. (Table 3) In addition there is an events adjudica-
tion committee, which will independently review and
adjudicate each clinical event blinded to treatment
randomization. Since all the imaging approaches are part
of standard clinical practice, no interim analysis is
planned, but there will be independent data safety moni-
toring board (DSMB), which will review the safety data
on a periodic basis; the frequency of the meetings and
the charter governing the DSMB will be finalized at the
first meeting of the DSMB.
Blood samples for the biomarkers ancillary study will
be stored at the Montreal Heart Institute central la-
boratory for analyses to be performed after study
completion.Trial status
At the time of this manuscript preparation, the IMAGE
IA trial is currently in the second year of active enroll-
ment. We have enrolled a total of 249 patients,
representing 20% of anticipated total enrollment. The
study is active in a total of 13 sites across Canada and
Finland. We anticipate study completion of enrollment
by December 2015.
Additional files
Additional file 1: Left ventricular remodeling and biomarkers
ancillary study – a synopsis.
Additional file 2: Standardization and quality assurance (IMAGE-QA).
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